The Atellica CI Analyzer testing system is the newest addition to Germany-based medical technology company Siemens Healthineers’ Atellica in vitro diagnostics portfolio for immunoassay and clinical chemistry testing.
The system aims to address the impact of staff shortages and drive revenue growth by prioritising speed and clinical equivalence. It helps in achieving clinical standardisation in every care setting.
Recommended White Papers
Recommended Buyers Guides
The testing system introduces workflow enhancements that enable laboratories to deliver more predictable turnaround times, reduce reporting burdens and allow staff to concentrate on essential laboratory operations.
Unilabs, a diagnostic services provider, signed a multi-year agreement of more than €200m ($218m) with Siemens in February 2023 to acquire more than 400 laboratory analysers, including the Atellica portfolio solutions, for improving its laboratory infrastructure.
The Atellica CI Analyzer received US Food and Drug Administration (FDA) clearance in July 2023 and is available in several other major global markets.
Atellica CI Analyzer details
The Atellica CI Analyzer, designed for continuous operations, combines integrated chemistry and immunoassay testing within a compact 1.9m² (20.4ft²) footprint, delivering swift and precise results crucial for patient care in critical settings.
The analyser is enhanced by advanced AI and comprehensive automation, making it adaptable to laboratory and care environments. Its sophisticated user interface is intuitive, simplifying complex tasks and increasing efficiency through a customisable dashboard that accelerates workflow.
The user interface includes onboard tools to assist with laboratory accreditation and simplifies training to optimise the user experience with guided workflows, and a lab evaluation suite. It allows the intelligent monitoring of supplies, consumables and common laboratory tasks from the home screen dashboard.
The analyser maintains regular assay studies with standard parameters, generating reports and allowing for data exportation, thereby streamlining laboratory evaluations.
Atellica CI Analyzer specifications
The Atellica CI Analyzer runs up to 1,120 tests per hour, including 600 photometric, 400 ion-selective electrode measurement technologies (IMTs), and 120 immunoassay tests per hour, with an onboard capacity of 113 assays, including 70 reagent clinical chemistry positions, three IMTs, 20 primary and 20 ancillary immunoassay positions.
The rack handler has input and output queues and can accommodate 60 samples in ten six-position racks with STAT testing capabilities. STAT sample processing can be done in less than 60 seconds.
The system uses random access sampling, with no common processing components for clinical chemistry and immunoassay analysis, maximising the throughput. It has a walkaway time of two hours and requires less than five minutes of hands-on daily maintenance.
Atellica CI Analyzer features
The analyser’s microvolume technology maximises the test yield from a single sample target. It features an IMT sensor that offers electrolyte analysis with automatic calibration. The analyser has up to six months of chemistry reagent onboard stability and calibration intervals of up to 200 days.
Environmental controls and consistent temperatures allow precise immunoassay reactions. Other features for producing quality immunoassay test results include temperature-controlled incubation, fast throughput for effective turnaround times and an independent wash ring.
The analyser has immunoassay reagents onboard stability of up to three months and calibration intervals of up to 90 days. It features user authentication, role-based authorisations and audit trails for increased security.
The system offers a comprehensive infectious disease menu with workflow-efficient HIV and hepatitis assays. The proprietary ELF™ blood test evaluates the risk of NASH liver fibrosis development.
The analyser also showcases a reproductive endocrinology menu, including Anti-Mullerian Hormone (AMH) to determine ovarian reserve, sFlt-1 and PlGF [placental growth factor] to aid in the prognosis of preeclampsia.
Additional features include total cardiac panels, such as BNP or NT-proBNP, and high-sensitivity troponin I, which is the only hs-cTnI assay with faster protocols supported in APACE, High-STEACS and HIGH-US cohorts.
Atellica CI Analyzer benefits
The Atellica CI Analyzer is designed to support standalone and satellite laboratories within larger health networks, providing uniformity in reagents, consumables and intelligent software that align with the capabilities of the Atellica Solution.
The analyser offers a comprehensive menu of more than 200 assays spanning 20 disease states, allowing individual laboratories to tailor their testing offerings to meet the specific clinical needs of their patient populations and manage demand effectively. Notably, the analyser can deliver results for more than 50 critical assays in less than 14 minutes, enhancing the speed of patient care.
In addition to its diagnostic capabilities, the Atellica CI Analyzer is engineered to be environmentally conscious, consuming less water and contributing to sustainability efforts
